What question did this study set out to answer?

This research aims to evaluate the clinical outcomes of LVAD implantation for advanced heart failure in a specific center.

February 12, 2026

Left ventricular assist device therapy for advanced heart failure: A single-center retrospective study

Key Points

This research aims to evaluate the clinical outcomes of LVAD implantation for advanced heart failure in a specific center.
Conducted a retrospective analysis of 28 patients who received LVAD implantation.
Compared preoperative and 3-month postoperative clinical data.
Measured outcomes including LVEDD, LVEF, NYHA class, and 6MWD.
All 28 patients successfully underwent LVAD implantation with an average ICU stay of 10 days.
After 3 months, LVEDD decreased significantly from 75.2 mm to 61.3 mm.
LVEF increased significantly from 22.7% to 34.8%, and 6MWD improved from 85 m to 356.1 m.
Complications included 7% hemorrhagic stroke and 3.5% rates for arrhythmia and renal failure.

Abstract

Background In China, Left Ventricular Assist Devices (LVADs) are increasingly adopted to improve the quality of life for patients with end-stage heart failure. This study aims to systematically present the clinical data and outcomes of LVAD implantations performed at Anhui Chest Hospital. Methods We retrospectively analyzed 28 consecutive patients who underwent LVAD implantation from October 2024 to July 2025. Preoperative baselines were compared with 3-months postoperative outcomes, including Left Ventricular End-Diastolic Diameter (LVEDD), Ejection Fraction (LVEF), NYHA functional class, and 6-Minute Walk Distance (6MWD). Adverse events were recorded. Results All 28 patients (20 males; mean age 59.7 ± 12.3 years) successfully underwent the procedure. The postoperative ICU stay was 10 ± 5.9 days. Complications within 90 days included hemorrhagic stroke (7%), malignant arrhythmia (3.5%), renal failure (3.5%), poor wound healing (3.5%), and one death (3.5%). No device malfunctions occurred. At 3 months, LVEDD significantly decreased (61.3 ± 5.8 vs 75.2 ± 9.4 mm), while LVEF (34.8 ± 9.8% vs 22.7 ± 5.6%) and 6MWD (356.1 ± 159.4 m vs 85 ± 49.6 m) significantly increased (all p < 0.01). All surviving patients improved to NYHA class I–II. Conclusion Preliminary results indicate that the application of Chinese LVADs demonstrates favorable clinical efficacy and acceptable safety profiles, serving as effective therapeutic strategies for advanced heart failure.

Mark Helpful

Bookmark

Relay